BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 30, 2025
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Feb. 10, 2020

Feb. 10, 2020
Biopharmas raising money in public or private financings, including: Adaptimmune, Assertio, Collegium, Mereo.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Med-tech firms raising money in public or private financings, including: Aurora Spine.
Read More
2-7-Sensome-Clotild.png

Sensome raises $9M series B funding round for Clotild guidewire

Feb. 7, 2020
By Bernard Banga
PARIS – Sensome SAS, of Palaiseau, France, has closed a second funding round, of $9 million, with its original French investors (Kurma Partners SA, Invest Partners SA, BNP Paribas Développement SA and the Paris-Saclay Seed Fund), now joined by the Japanese-based Asahi Intecc Co. Ltd.
Read More

Financings for Feb. 7, 2020

Feb. 7, 2020
Biopharmas raising money in public or private financings, including: Adma, AGTC, Dare, Inventiva, Miragen, Orphazyme, Phio, Rapt, Salarius, Tonix.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Med-tech firms raising money in public or private financings, including: Connectyx Technologies, Lunaphore Technologies, Pentixapharm, Rewalk Robotics.
Read More
European Union flag, coins

Azafaros closes $28M series A for dual-acting enzyme inhibitors in lysosomal storage disease

Feb. 6, 2020
By Cormac Sheridan
DUBLIN – Azafaros BV raised €25 million (US$27.5 million) to develop orally available azasugar drugs with potential application to multiple lysosomal storage diseases.
Read More

Financings for Feb. 6, 2020

Feb. 6, 2020
Biopharmas raising money in public or private financings, including: AGTC, Arch Biopartners, Atyr, Beam, Chi-Med, Cortexyme, Kineticos, Moleculin, Pentixapharm, Sonoma, Valo.
Read More
2-5-Lumos-Febridx.png

Lumos Diagnostics scoops up $15M in series A to back Febridx test

Feb. 5, 2020
By Liz Hollis
With an eye toward expanding the reach of its Febridx rapid point-of-care (POC) test, Lumos Diagnostics Holdings Pty. Ltd. has seen the closing of a $15 million series A round from Australia’s Planet Innovation. The funds will back a U.S. FDA pivotal clinical trial, as well as additional development and manufacturing resources for the company’s expanding full-service POC business.
Read More

Maat Pharma edges toward FMT data readout with $20M series B round

Feb. 5, 2020
By Cormac Sheridan
DUBLIN – Maat Pharma SA closed an €18 million (US$19.9 million) series B round to continue development of its standardized, off-the-shelf fecal microbiota transplant (FMT) therapy, MaaT-013.
Read More

Financings for Feb. 5, 2020

Feb. 5, 2020
Med-tech firms raising money in public or private financings, including: Integra Lifesciences Holdings, Itamar Medical, Jenavalve Technology, Verana Health.
Read More
Previous 1 2 … 593 594 595 596 597 598 599 600 601 … 641 642 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 30, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Businessman, businesswoman handshake

    Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

    BioWorld
    Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
  • Asia focused map inside light bulb

    Big pharma taps fast Asia innovation in search of next Keytruda

    BioWorld
    Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing